REGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference
February 09 2017 - 7:00AM
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company
focused on the development, commercialization and licensing of
recombinant adeno-associated virus (AAV) gene therapy based on its
proprietary NAV® Technology Platform, today announced that it will
participate in the 6th Annual LEERINK Partners Global Healthcare
Conference on Wednesday, February 15, 2017 at the Lotte New York
Palace in New York City.
A live webcast of REGENXBIO’s presentation is scheduled to begin
at 10:30 a.m. ET and will feature a fireside chat with Kenneth T.
Mills, President and Chief Executive Officer. The live webcast can
be accessed in the Investors section of REGENXBIO’s website
at www.regenxbio.com. An archived replay of the webcast will
be available on the same website for approximately 30 days
following the presentation.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the
development, commercialization and licensing of recombinant
adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV®
Technology Platform, a proprietary AAV gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to
transform the lives of patients suffering from severe diseases with
significant unmet medical need by developing and commercializing in
vivo gene therapy products based on REGENXBIO’s NAV Technology
Platform. REGENXBIO seeks to accomplish this mission through a
combination of internal development efforts and third-party NAV
Technology Platform Licensees. REGENXBIO and its licensees are
applying the NAV Technology Platform in the development of a broad
pipeline of candidates in multiple therapeutic areas.
CONTACT:
Investors
Heather Savelle, 646-395-3734
heather@argotpartners.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024